Cancer and Leukemia Group B

描述（由申请人提供）：杜克大学医学中心目前正在完成其作为癌症和白血病组B（CALGB）成员的第四个赠款周期。在过去的二十年里，杜克一直是前五名的机构在整体患者的增加。当前申请的目标和具体目标是继续这种高水平的患者招募，并结合我们的教师在治疗试验和相关科学研究的发展中的广泛科学参与。另一个目标是进一步发展我们的临床试验组织，通过提供广泛的癌症临床试验，不仅在杜克，而且在北卡罗来纳州和整个美国东南部的研究分支机构服务不足的社区通过我们的杜克肿瘤学网络（DON）。在当前的资助周期中，杜克大学招募了866名患者，整个DON招募了近1900名患者。这种对CALGB活动的高水平临床承诺与杜克学院的高水平科学参与相匹配。特别的优势领域包括乳腺癌和相关研究，老年人癌症，白血病/淋巴瘤和呼吸道癌症和胸外科。教师招聘扩大了我们在所有这些领域的实力，以及在GI和GU癌症计划提供了重大增长。杜克大学的教师在CALGB生物标志物为基础的研究和基因组为基础的治疗试验作出了重大贡献。为了改善监管监督和有效利用资源，杜克癌症临床试验已重组为癌症中心内的肿瘤学研究中心（SBR）实体，其中包括CALGB活动。SBR/ CALGB负责监督杜克和整个DON的疾病和特定临床研究团队，其中包括北卡罗来纳州的10个社区站点，由杜克教师和研究护士组成，以及11个研究附属站点。这一组织结构是在过去20年中在杰弗里·克劳福德博士的指导下发展起来的，他是CALGB活动的主要研究员。杜克的活动通过与总部位于杜克的CALGB生物统计学和数据管理中心的密切互动得到进一步加强，Stephen乔治博士也是杜克综合癌症中心的生物统计学主任。在下一个资助周期中，我们建议利用这些资源进一步增加合作组临床试验的患者招募，提高我们在组内的科学参与，并扩大服务不足人群的临床试验。

DESCRIPTION (provided by applicant): Duke University Medical Center is currently completing its fourth grant cycle as a member of Cancer and Leukemia Group B (CALGB). Over the last two decades, Duke has consistently been one of the top five institutions in overall patient accrual. The goal and specific aims of the current application are to continue this high level of patient enrollment, combined with broad scientific participation by our faculty in the development of treatment trials and correlative science studies. An additional aim is to further develop our clinical trials organization by providing broad access to cancer clinical trials, not only at Duke, but also in underserved communities of North Carolina and research affiliates across the Southeast United States through our Duke Oncology Network (DON). In the current grant cycle, 866 patients were enrolled at Duke and nearly 1900 patients across the DON. This high level of clinical commitment to CALGB activities is matched by a high level of scientific participation by Duke Faculty. Particular areas of strength include Breast Cancer and Correlative Studies, Cancer in the Elderly, Leukemia/Lymphoma and Respiratory Cancer and Thoracic Surgery. Faculty recruitment has expanded our strength in all of these areas, as well as provided major growth in Gl and GU cancer programs. Duke faculty have made substantial contributions in CALGB biomarker based studies and genomic based treatment trials. To improve regulatory oversight and efficient use of resources, Duke cancer clinical trials have been reorganized into an Oncology Site Based Research (SBR) entity within the Cancer Center which includes CALGB activities. The SBR/ CALGB oversees disease and site specific clinical research teams at Duke and throughout DON, which includes 10 community sites in North Carolina, staffed by Duke faculty and research nurses, as well as 11 research affiliate sites. This organizational structure has been developed over the last 20 years under the direction of Dr. Jeffrey Crawford, who serves as the Principal Investigator of CALGB activities. Activities at Duke are further enhanced by the close interaction with the CALGB biostatistics and data management center headquartered at Duke, under the direction of Dr. Stephen George, who is also Director of Biostatistics at the Duke Comprehensive Cancer Center. In the next grant cycle, we propose to utilize these resources to further increase our patient enrollment on cooperative group clinical trials, enhance our scientific participation within the group and expand access to clinical trials for underserved populations.